[Toxicities of targeted therapies and their management in renal cancer: methodology of guidelines].
Advanced renal cell carcinoma (RCC) is associated with a poor prognosis and is refractory to standard chemotherapy. Recent progress in the understanding of molecular biology and pathogenesis of renal cell cancer has been translated into the development of new therapeutic strategies. The management of metastatic RCC has been revolutionized with the development of targeted molecular therapies against VEGF-VEGFR and mTOR. Randomized phase III clinical trials demonstrated clinical benefit for patients with advanced RCC in overall survival and progression free survival. Guidelines for the management of side effects induced by these targeted therapies seem to be warranted.